<DOC>
	<DOC>NCT01579903</DOC>
	<brief_summary>This study is being conducted to compare how moroctocog alfa (AF-CC) acts in the body when administered as 2 different dose presentations. The first is the current product vials with prefilled diluent syringes and the second is a new dual-chamber syringe dose presentation.</brief_summary>
	<brief_title>Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)</brief_title>
	<detailed_description>This study is being conducted in order to satisfy a post-approval EMA commitment to compare the pharmacokinetics of the 2 dose presentations used in this study.</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male patients at least 18 years old with severe or moderately severe hemophilia A (facto VIII concentration less than or equal to 2%). Negative test for facto VIII inhibitor. If applicable, HIV or hepatitis treatment is stable at the time of enrollment. Ability to abstain from use of FVIII products for 72 hours at a time. History of any positive test result for factor VIII inhibitor. Presence of any bleeding disorder in addition to Hemophilia A. Body weight less than 50 kg. History of alcoholism. Treatment with investigational drug or device within 30 days prior to the Screening visit.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>moroctocog alfa (AF-CC)</keyword>
	<keyword>ReFacto AF</keyword>
	<keyword>dual-chamber syringe</keyword>
	<keyword>bioavailability</keyword>
</DOC>